(CYRX) Cryoport - Overview
Stock: Cryogenic Shippers, Freezers, Bioservices, Monitoring
EPS (Earnings per Share)
Revenue
| Risk 5d forecast | |
|---|---|
| Volatility | 74.2% |
| Relative Tail Risk | -18.5% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | 0.66 |
| Alpha | 2.77 |
| Character TTM | |
|---|---|
| Beta | 1.539 |
| Beta Downside | 1.717 |
| Drawdowns 3y | |
|---|---|
| Max DD | 80.50% |
| CAGR/Max DD | -0.34 |
Description: CYRX Cryoport December 29, 2025
Cryoport, Inc. (NASDAQ:CYRX) delivers end-to-end temperature-controlled logistics and cryogenic storage solutions for biopharma, animal health, and reproductive medicine markets. Its business splits into two segments: Life Sciences Services, which handles shipping, biostorage, and sample-management services, and Life Sciences Products, which sells cryogenic freezers, dewars, and related accessories through direct sales and distributors.
In FY 2023 the company reported $215 million in revenue, up roughly 12 % year-over-year, driven by a 30 % increase in shipments of its Express and ELITE shippers for cell-therapy clinical trials. The gross margin held steady at 46 %, while the backlog of long-term service contracts grew to $140 million, indicating recurring demand. However, operating cash flow remained modest ($12 million), reflecting ongoing investments in R&D and expansion of its biostorage network.
Key macro drivers include the rapid growth of the global cold-chain market-projected to reach $250 billion by 2028-and the accelerating pipeline of mRNA vaccines, gene-editing therapies, and personalized cell therapies that require ultra-low temperature transport. Regulatory pressure for secure, temperature-verified shipments further supports Cryoport’s value proposition.
For a deeper quantitative view, see the CYRX valuation dashboard on ValueRay.
Piotroski VR‑10 (Strict, 0-10) 2.0
| Net Income: 67.6m TTM > 0 and > 6% of Revenue |
| FCF/TA: -0.04 > 0.02 and ΔFCF/TA 0.45 > 1.0 |
| NWC/Revenue: 241.1% < 20% (prev 151.3%; Δ 89.80% < -1%) |
| CFO/TA -0.02 > 3% & CFO -15.0m > Net Income 67.6m |
| Net Debt/EBITDA: error (EBITDA <= 0) |
| Current Ratio: 15.92 > 1.5 & < 3 |
| Outstanding Shares: last quarter (50.1m) vs 12m ago 1.43% < -2% |
| Gross Margin: 46.58% > 18% (prev 0.43%; Δ 4615 % > 0.5%) |
| Asset Turnover: 25.79% > 50% (prev 27.21%; Δ -1.42% > 0%) |
| Interest Coverage Ratio: -18.35 > 6 (EBITDA TTM -14.1m / Interest Expense TTM 2.36m) |
Altman Z'' -2.03
| A: 0.59 (Total Current Assets 489.5m - Total Current Liabilities 30.7m) / Total Assets 773.9m |
| B: -0.86 (Retained Earnings -668.2m / Total Assets 773.9m) |
| C: -0.06 (EBIT TTM -43.4m / Avg Total Assets 737.8m) |
| D: -2.58 (Book Value of Equity -673.6m / Total Liabilities 261.1m) |
| Altman-Z'' Score: -2.03 = D |
Beneish M -3.40
| DSRI: 0.77 (Receivables 33.4m/43.5m, Revenue 190.3m/190.9m) |
| GMI: 0.91 (GM 46.58% / 42.62%) |
| AQI: 0.64 (AQ_t 0.21 / AQ_t-1 0.33) |
| SGI: 1.00 (Revenue 190.3m / 190.9m) |
| TATA: 0.11 (NI 67.6m - CFO -15.0m) / TA 773.9m) |
| Beneish M-Score: -3.40 (Cap -4..+1) = AA |
What is the price of CYRX shares?
Over the past week, the price has changed by -7.82%, over one month by -4.07%, over three months by +4.31% and over the past year by +27.78%.
Is CYRX a buy, sell or hold?
- StrongBuy: 4
- Buy: 2
- Hold: 4
- Sell: 0
- StrongSell: 0
What are the forecasts/targets for the CYRX price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 13.2 | 40.2% |
| Analysts Target Price | 13.2 | 40.2% |
| ValueRay Target Price | 8.4 | -10.8% |
CYRX Fundamental Data Overview January 29, 2026
P/S = 2.101
P/B = 1.0734
Revenue TTM = 190.3m USD
EBIT TTM = -43.4m USD
EBITDA TTM = -14.1m USD
Long Term Debt = 186.1m USD (from longTermDebt, last quarter)
Short Term Debt = 9.11m USD (from shortTermDebt, last quarter)
Debt = 230.9m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = -25.0m USD (from netDebt column, last quarter)
Enterprise Value = 321.8m USD (512.2m + Debt 230.9m - CCE 421.3m)
Interest Coverage Ratio = -18.35 (Ebit TTM -43.4m / Interest Expense TTM 2.36m)
EV/FCF = -9.90x (Enterprise Value 321.8m / FCF TTM -32.5m)
FCF Yield = -10.10% (FCF TTM -32.5m / Enterprise Value 321.8m)
FCF Margin = -17.08% (FCF TTM -32.5m / Revenue TTM 190.3m)
Net Margin = 35.52% (Net Income TTM 67.6m / Revenue TTM 190.3m)
Gross Margin = 46.58% ((Revenue TTM 190.3m - Cost of Revenue TTM 101.6m) / Revenue TTM)
Gross Margin QoQ = 48.21% (prev 47.03%)
Tobins Q-Ratio = 0.42 (Enterprise Value 321.8m / Total Assets 773.9m)
Interest Expense / Debt = 0.23% (Interest Expense 526.0k / Debt 230.9m)
Taxrate = 21.0% (US default 21%)
NOPAT = -34.2m (EBIT -43.4m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 15.92 (Total Current Assets 489.5m / Total Current Liabilities 30.7m)
Debt / Equity = 0.45 (Debt 230.9m / totalStockholderEquity, last quarter 515.4m)
Debt / EBITDA = 1.77 (negative EBITDA) (Net Debt -25.0m / EBITDA -14.1m)
Debt / FCF = 0.77 (negative FCF - burning cash) (Net Debt -25.0m / FCF TTM -32.5m)
Total Stockholder Equity = 428.7m (last 4 quarters mean from totalStockholderEquity)
RoA = 9.16% (Net Income 67.6m / Total Assets 773.9m)
RoE = 15.76% (Net Income TTM 67.6m / Total Stockholder Equity 428.7m)
RoCE = -7.05% (EBIT -43.4m / Capital Employed (Equity 428.7m + L.T.Debt 186.1m))
RoIC = -5.59% (negative operating profit) (NOPAT -34.2m / Invested Capital 612.9m)
WACC = 8.05% (E(512.2m)/V(743.1m) * Re(11.59%) + D(230.9m)/V(743.1m) * Rd(0.23%) * (1-Tc(0.21)))
Discount Rate = 11.59% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 100.0 | Cagr: 1.18%
Fair Price DCF = unknown (Cash Flow -32.5m)
EPS Correlation: 9.92 | EPS CAGR: 7.28% | SUE: 0.55 | # QB: 0
Revenue Correlation: -57.53 | Revenue CAGR: -6.29% | SUE: 0.29 | # QB: 0
EPS next Quarter (2026-03-31): EPS=-0.14 | Chg30d=-0.003 | Revisions Net=-2 | Analysts=4
EPS next Year (2026-12-31): EPS=-0.59 | Chg30d=-0.009 | Revisions Net=-1 | Growth EPS=+29.9% | Growth Revenue=+9.1%